Psoriatec (anthralin cream 1.0%, USP) is a smooth, yellow cream containing 1% anthralin USP in an aqueous cream base of glyceryl monolaurate, glyceryl monomyristate, citric acid, sodium hydroxide and purified water. For topical dermatological use only.
For the topical treatment of psoriasis.
Media Articles Related to Psoriatec (Anthralin)
In diseases like cancers and psoriasis, degradation is key to the activity of the miR-21 oncomiR
Source: Cancer / Oncology News From Medical News Today [2014.07.23]
Scientists from the RIKEN Center for Life Science Technologies in Japan have gained new clues that suggest the existence of a regulatory network that contributes to the irregular proliferation of...
Psoriasis Foundation drives efforts to cure psoriasis and psoriatic arthritis with new strategic plan
Source: Arthritis / Rheumatology News From Medical News Today [2014.07.11]
National Psoriasis Foundation will double the number of researchers studying psoriasis and psoriatic arthritis while also cutting in half the number of people who say these chronic conditions are a...
Two-gene test differentiates psoriasis from eczema
Source: Dermatology News From Medical News Today [2014.07.11]
After analyzing the molecular processes involved, researchers in Germany have developed a test that can differentiate psoriasis from eczema on the basis of only two genes.
Two pivotal psoriasis studies demonstrate secukinumab achieves clear or almost clear skin in majority of patients
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.07.10]
New data published online in the New England Journal of Medicine (NEJM) confirm the superior efficacy of secukinumab*, an interleukin-17A (IL-17A) inhibitor, over a NICE-recommended treatment...
New Psoriasis Drug Shows Promise in Trials
Source: MedicineNet Clinical Trials Specialty [2014.07.10]
Title: New Psoriasis Drug Shows Promise in Trials
Category: Health News
Created: 7/9/2014 5:36:00 PM
Last Editorial Review: 7/10/2014 12:00:00 AM
Published Studies Related to Psoriatec (Anthralin)
Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. 
CONCLUSION: The present pilot study showed that the use of azelaic acid gave similar results to anthralin with regard to hair regrowth, and that it can be an effective topical therapy for patchy AA. More extensive trials are necessary, however, to reach a definitive conclusion.
Effect of H1-receptor blockade on anthralin inflammation. 
The effect of terfenadine, an H1-receptor antagonist, on anthralin inflammation was studied in 12 subjects. Subjects were randomised to receive terfenadine 60 mg or placebo b.d... This study shows that H1-receptor blockade does not inhibit anthralin inflammation.
Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis. [1988.04]
A prospective randomized trial of anthralin in Lassar's paste compared with anthralin in 0.0125% clobetasol propionate in the treatment of chronic plaque psoriasis was undertaken. The psoriatic skin of patients treated with the corticosteroid-anthralin combination cleared significantly more quickly than those treated with anthralin alone, with a mean time to clearance of 14.9 days compared with 18.5 days, and with lower concentrations of anthralin...
An EPR method for estimating activity of antioxidants in mouse skin using an anthralin-derived radical model. [2010.03]
Inhibitory effects of intravenously or orally administered antioxidants on the anthralin-derived radical generated in skin (mainly in the epidermis) of living mice by ultraviolet-A (UVA) irradiation were estimated. Anthralin was applied to the dorsal skin of living mice and the mice were then exposed to UVA.
Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy. [2009.12]
BACKGROUND: Psoriatic lesions are characterized by induration, scaling and erythema. Erythema is a result of inflammation and increased microvascular blood flow. Anthralin is the strongest topical antipsoriatic drug that causes clearing of psoriatic lesions and temporary remission. OBJECTIVE: The objective evaluation of skin perfusion might be a suitable way to gain a better insight in the pathophysiological process of this disease and to evaluate the response to antipsoriatic anthralin therapy... CONCLUSIONS: Vascular perfusion is increased in psoriatic lesions as demonstrated by remission spectroscopy. NADH-fluorescence is reduced in lesional psoriatic skin and in anthralin-induced erythema. FRIS is a suitable tool for objective evaluation of the cutaneous response to antipsoriatic treatment.
Clinical Trials Related to Psoriatec (Anthralin)
Steroids Added to Dithranol and Narrow Band UVB (UVBnb) in Psoriasis [Recruiting]
(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
loss of PASI improvement obtained through the antecedent treatment.
(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).
- Trial with medicinal product
Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis [Recruiting]
This study is to determine the effect of adalimumab on inflammation of blood vessels that
could lead to heart attack in patients with psoriasis. Changes to the carotid artery and
ascending aorta will be evaluated in patients treated with adalimumab (systemic treatment)
and compared against patients treated with a topical treatment that does not affect the